# A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

> **NCT02605434** · PHASE3 · UNKNOWN · sponsor: **Intec Pharma Ltd.** · enrollment: 420 (estimated)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Accordion Pill™ Carbidopa/Levodopa
- **DRUG:** Sinemet®
- **DRUG:** Placebo -AP-CD/LD
- **DRUG:** Placebo- Sinemet

## Key facts

- **NCT ID:** NCT02605434
- **Lead sponsor:** Intec Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2019-07
- **Final completion:** 2019-12
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605434, "A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02605434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*